Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 259

1.

Cancer Biology and Survival Analysis in Cancer Trials: Restricted Mean Survival Time Analysis versus Hazard Ratios.

A'Hern RP.

Clin Oncol (R Coll Radiol). 2018 Sep;30(9):e75-e80. doi: 10.1016/j.clon.2018.04.011.

PMID:
29776805
2.

Real-time imaging of single neuronal cell apoptosis in patients with glaucoma.

Cordeiro MF, Normando EM, Cardoso MJ, Miodragovic S, Jeylani S, Davis BM, Guo L, Ourselin S, A'Hern R, Bloom PA.

Brain. 2017 Jun 1;140(6):1757-1767. doi: 10.1093/brain/awx088.

3.

Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials?

A'Hern RP.

J Clin Oncol. 2016 Oct 1;34(28):3474-6. doi: 10.1200/JCO.2016.67.8045. Epub 2016 Aug 9. No abstract available.

PMID:
27507871
4.

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A'Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS.

N Engl J Med. 2015 Oct 29;373(18):1697-708. doi: 10.1056/NEJMoa1506859.

5.

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).

Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS.

Ann Oncol. 2015 Dec;26(12):2505-6. doi: 10.1093/annonc/mdv478. Epub 2015 Oct 13. No abstract available.

PMID:
26467471
6.

Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial.

Jamal-Hanjani M, A'Hern R, Birkbak NJ, Gorman P, Grönroos E, Ngang S, Nicola P, Rahman L, Thanopoulou E, Kelly G, Ellis P, Barrett-Lee P, Johnston SR, Bliss J, Roylance R, Swanton C.

Ann Oncol. 2015 Jul;26(7):1340-6. doi: 10.1093/annonc/mdv178. Epub 2015 May 23.

PMID:
26003169
7.

A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma.

Seddon B, Scurr M, Jones RL, Wood Z, Propert-Lewis C, Fisher C, Flanagan A, Sunkersing J, A'Hern R, Whelan J, Judson I.

Clin Sarcoma Res. 2015 May 16;5:13. doi: 10.1186/s13569-015-0029-8. eCollection 2015.

8.

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.

Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS; Definition for the Assessment of Time-to-event Endpoints in Cancer Trials Initiative.

Ann Oncol. 2015 May;26(5):873-9. doi: 10.1093/annonc/mdv106. Epub 2015 Feb 27. Review. Erratum in: Ann Oncol. 2015 Dec;26(12):2505-6.

PMID:
25725046
9.

Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039).

Leary A, Evans A, Johnston SR, A'Hern R, Bliss JM, Sahoo R, Detre S, Haynes BP, Hills M, Harper-Wynne C, Bundred N, Coombes G, Smith I, Dowsett M.

Clin Cancer Res. 2015 Jul 1;21(13):2932-40. doi: 10.1158/1078-0432.CCR-14-1428. Epub 2014 Nov 14.

10.

Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy.

Sheri A, Smith IE, Johnston SR, A'Hern R, Nerurkar A, Jones RL, Hills M, Detre S, Pinder SE, Symmans WF, Dowsett M.

Ann Oncol. 2015 Jan;26(1):75-80. doi: 10.1093/annonc/mdu508. Epub 2014 Oct 30.

PMID:
25361988
11.

Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer.

Patani N, Dunbier AK, Anderson H, Ghazoui Z, Ribas R, Anderson E, Gao Q, A'hern R, Mackay A, Lindemann J, Wellings R, Walker J, Kuter I, Martin LA, Dowsett M.

Clin Cancer Res. 2014 Aug 1;20(15):3962-73. doi: 10.1158/1078-0432.CCR-13-1378. Epub 2014 Jun 10.

12.

Radiotherapy for breast cancer, the TARGIT-A trial.

Haviland JS, A'Hern R, Bentzen SM, Whelan T, Bliss JM.

Lancet. 2014 May 17;383(9930):1716-7. doi: 10.1016/S0140-6736(14)60826-6. No abstract available.

PMID:
24835609
13.

Predictive performance of microarray gene signatures: impact of tumor heterogeneity and multiple mechanisms of drug resistance.

Ng CKY, Weigelt B, A'Hern R, Bidard FC, Lemetre C, Swanton C, Shen R, Reis-Filho JS.

Cancer Res. 2014 Jun 1;74(11):2946-2961. doi: 10.1158/0008-5472.CAN-13-3375. Epub 2014 Apr 4.

14.

DNA double-strand break repair and induction of apoptosis in ex vivo irradiated blood lymphocytes in relation to late normal tissue reactions following breast radiotherapy.

Chua ML, Horn S, Somaiah N, Davies S, Gothard L, A'Hern R, Yarnold J, Rothkamm K.

Radiat Environ Biophys. 2014 May;53(2):355-64. doi: 10.1007/s00411-014-0531-z. Epub 2014 Mar 13.

PMID:
24622963
15.

Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.

Arnedos M, Drury S, Afentakis M, A'Hern R, Hills M, Salter J, Smith IE, Reis-Filho JS, Dowsett M.

Ann Oncol. 2014 Mar;25(3):605-10. doi: 10.1093/annonc/mdt575. Epub 2014 Feb 12.

16.

Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer.

Irshad S, Gillett C, Pinder SE, A'hern RP, Dowsett M, Ellis IO, Bartlett JM, Bliss JM, Hanby A, Johnston S, Barrett-Lee P, Ellis P, Tutt A.

Breast Cancer Res Treat. 2014 Apr;144(2):331-41. doi: 10.1007/s10549-014-2855-4. Epub 2014 Feb 12.

PMID:
24519386
17.

Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast.

Natrajan R, Wilkerson PM, Marchiò C, Piscuoglio S, Ng CK, Wai P, Lambros MB, Samartzis EP, Dedes KJ, Frankum J, Bajrami I, Kopec A, Mackay A, A'hern R, Fenwick K, Kozarewa I, Hakas J, Mitsopoulos C, Hardisson D, Lord CJ, Kumar-Sinha C, Ashworth A, Weigelt B, Sapino A, Chinnaiyan AM, Maher CA, Reis-Filho JS.

J Pathol. 2014 Apr;232(5):553-65. doi: 10.1002/path.4325. Epub 2014 Feb 5.

18.

Taxane benefit in breast cancer--a role for grade and chromosomal stability.

A'Hern RP, Jamal-Hanjani M, Szász AM, Johnston SR, Reis-Filho JS, Roylance R, Swanton C.

Nat Rev Clin Oncol. 2013 Jun;10(6):357-64. doi: 10.1038/nrclinonc.2013.67. Epub 2013 May 7. Review.

PMID:
23648828
19.

Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer.

Bartlett JM, A'hern R, Piper T, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, Bliss JM, Ellis P, Barrett-Lee PJ.

Breast Cancer Res Treat. 2013 Apr;138(3):773-81. doi: 10.1007/s10549-013-2489-y. Epub 2013 Mar 28.

PMID:
23535839
20.

Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance.

Dunbier AK, Ghazoui Z, Anderson H, Salter J, Nerurkar A, Osin P, A'hern R, Miller WR, Smith IE, Dowsett M.

Clin Cancer Res. 2013 May 15;19(10):2775-86. doi: 10.1158/1078-0432.CCR-12-1000. Epub 2013 Mar 14.

21.

Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations.

Wetterskog D, Wilkerson PM, Rodrigues DN, Lambros MB, Fritchie K, Andersson MK, Natrajan R, Gauthier A, Di Palma S, Shousha S, Gatalica Z, Töpfer C, Vukovic V, A'Hern R, Weigelt B, Vincent-Salomon A, Stenman G, Rubin BP, Reis-Filho JS.

Histopathology. 2013 Mar;62(4):543-50. doi: 10.1111/his.12050. Epub 2013 Feb 12.

22.

Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer.

Haynes BP, Viale G, Galimberti V, Rotmensz N, Gibelli B, A'Hern R, Smith IE, Dowsett M.

Breast Cancer Res Treat. 2013 Feb;138(1):157-65. doi: 10.1007/s10549-013-2426-0. Epub 2013 Feb 3.

PMID:
23378065
23.

Correlation of age and HRT use with breast density as assessed by Quantra™.

Skippage P, Wilkinson L, Allen S, Roche N, Dowsett M, A'hern R.

Breast J. 2013 Jan-Feb;19(1):79-86. doi: 10.1111/tbj.12046. Epub 2012 Dec 10.

PMID:
23230974
24.

Correlation of in vitro lymphocyte radiosensitivity and gene expression with late normal tissue reactions following curative radiotherapy for breast cancer.

Finnon P, Kabacik S, MacKay A, Raffy C, A'Hern R, Owen R, Badie C, Yarnold J, Bouffler S.

Radiother Oncol. 2012 Dec;105(3):329-36. doi: 10.1016/j.radonc.2012.10.007. Epub 2012 Nov 15.

PMID:
23157981
25.

Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.

Martin LA, Pancholi S, Farmer I, Guest S, Ribas R, Weigel MT, Thornhill AM, Ghazoui Z, A'Hern R, Evans DB, Lane HA, Johnston SR, Dowsett M.

Breast Cancer Res. 2012 Oct 17;14(5):R132. doi: 10.1186/bcr3330.

26.

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin.

Ploquin A, Olmos D, Lacombe D, A'Hern R, Duhamel A, Twelves C, Marsoni S, Morales-Barrera R, Soria JC, Verweij J, Voest EE, Schöffski P, Schellens JH, Kramar A, Kristeleit RS, Arkenau HT, Kaye SB, Penel N.

Br J Cancer. 2012 Sep 25;107(7):1025-30. doi: 10.1038/bjc.2012.371. Epub 2012 Aug 21.

27.

Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer.

Weigel MT, Banerjee S, Arnedos M, Salter J, A'Hern R, Dowsett M, Martin LA.

Ann Oncol. 2013 Jan;24(1):126-33. doi: 10.1093/annonc/mds240. Epub 2012 Aug 2.

PMID:
22865780
28.

Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.

Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP, Dowsett M.

J Clin Oncol. 2012 Aug 20;30(24):2977-80. doi: 10.1200/JCO.2012.42.0273. Epub 2012 Jul 16.

PMID:
22802308
29.

Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer.

Barton S, Zabaglo L, A'Hern R, Turner N, Ferguson T, O'Neill S, Hills M, Smith I, Dowsett M.

Br J Cancer. 2012 May 22;106(11):1760-5. doi: 10.1038/bjc.2012.166. Epub 2012 Apr 24.

30.

Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients.

Ferraldeschi R, Arnedos M, Hadfield KD, A'Hern R, Drury S, Wardley A, Howell A, Evans DG, Roberts SA, Smith I, Newman WG, Dowsett M.

Breast Cancer Res Treat. 2012 Jun;133(3):1191-8. doi: 10.1007/s10549-012-2010-z. Epub 2012 Mar 15.

PMID:
22418701
31.

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer.

Pinhel I, Hills M, Drury S, Salter J, Sumo G, A'Hern R, Bliss JM, Sestak I, Cuzick J, Barrett-Lee P, Harris A, Dowsett M; NCRI Adjuvant Breast Cancer Trial Management Group.

Breast Cancer Res. 2012 Mar 14;14(2):R46.

32.

A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers.

Natrajan R, Mackay A, Lambros MB, Weigelt B, Wilkerson PM, Manie E, Grigoriadis A, A'Hern R, van der Groep P, Kozarewa I, Popova T, Mariani O, Turaljic S, Furney SJ, Marais R, Rodruigues DN, Flora AC, Wai P, Pawar V, McDade S, Carroll J, Stoppa-Lyonnet D, Green AR, Ellis IO, Swanton C, van Diest P, Delattre O, Lord CJ, Foulkes WD, Vincent-Salomon A, Ashworth A, Stern MH, Reis-Filho JS.

J Pathol. 2012 May;227(1):29-41. doi: 10.1002/path.4003. Epub 2012 Feb 23.

33.

Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors.

Olmos D, A'hern RP, Marsoni S, Morales R, Gomez-Roca C, Verweij J, Voest EE, Schöffski P, Ang JE, Penel N, Schellens JH, Del Conte G, Brunetto AT, Evans TR, Wilson R, Gallerani E, Plummer R, Tabernero J, Soria JC, Kaye SB.

J Clin Oncol. 2012 Mar 20;30(9):996-1004. doi: 10.1200/JCO.2010.34.5074. Epub 2012 Feb 21.

PMID:
22355064
34.

Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.

Hernandez L, Wilkerson PM, Lambros MB, Campion-Flora A, Rodrigues DN, Gauthier A, Cabral C, Pawar V, Mackay A, A'Hern R, Marchiò C, Palacios J, Natrajan R, Weigelt B, Reis-Filho JS.

J Pathol. 2012 May;227(1):42-52. doi: 10.1002/path.3990. Epub 2012 Mar 21.

35.

Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.

Dowsett M, Smith I, Robertson J, Robison L, Pinhel I, Johnson L, Salter J, Dunbier A, Anderson H, Ghazoui Z, Skene T, Evans A, A'Hern R, Iskender A, Wilcox M, Bliss J.

J Natl Cancer Inst Monogr. 2011;2011(43):120-3. doi: 10.1093/jncimonographs/lgr034.

PMID:
22043057
36.

Immunophenotypic and genomic characterization of papillary carcinomas of the breast.

Duprez R, Wilkerson PM, Lacroix-Triki M, Lambros MB, MacKay A, A'Hern R, Gauthier A, Pawar V, Colombo PE, Daley F, Natrajan R, Ward E, MacGrogan G, Arbion F, Michenet P, Weigelt B, Vincent-Salomon A, Reis-Filho JS.

J Pathol. 2012 Feb;226(3):427-441. doi: 10.1002/path.3032. Epub 2011 Dec 9.

37.

Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers.

Wetterskog D, Lopez-Garcia MA, Lambros MB, A'Hern R, Geyer FC, Milanezi F, Cabral MC, Natrajan R, Gauthier A, Shiu KK, Orr N, Shousha S, Gatalica Z, Mackay A, Palacios J, Reis-Filho JS, Weigelt B.

J Pathol. 2012 Jan;226(1):84-96. doi: 10.1002/path.2974. Epub 2011 Oct 20.

PMID:
22015727
38.

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.

Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF; International Ki-67 in Breast Cancer Working Group.

J Natl Cancer Inst. 2011 Nov 16;103(22):1656-64. doi: 10.1093/jnci/djr393. Epub 2011 Sep 29.

39.

Residual DNA and chromosomal damage in ex vivo irradiated blood lymphocytes correlated with late normal tissue response to breast radiotherapy.

Chua ML, Somaiah N, A'Hern R, Davies S, Gothard L, Yarnold J, Rothkamm K.

Radiother Oncol. 2011 Jun;99(3):362-6. doi: 10.1016/j.radonc.2011.05.071. Epub 2011 Jun 23.

PMID:
21704405
40.

Inter-individual and inter-cell type variation in residual DNA damage after in vivo irradiation of human skin.

Chua ML, Somaiah N, Bourne S, Daley F, A'hern R, Nuta O, Davies S, Herskind C, Pearson A, Warrington J, Helyer S, Owen R, Yarnold J, Rothkamm K.

Radiother Oncol. 2011 May;99(2):225-30. doi: 10.1016/j.radonc.2011.04.009. Epub 2011 May 26.

PMID:
21620495
41.

Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement.

Mackay A, Weigelt B, Grigoriadis A, Kreike B, Natrajan R, A'Hern R, Tan DS, Dowsett M, Ashworth A, Reis-Filho JS.

J Natl Cancer Inst. 2011 Apr 20;103(8):662-73. doi: 10.1093/jnci/djr071. Epub 2011 Mar 18.

42.

Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer.

Anderson H, Hills M, Zabaglo L, A'hern R, Leary AF, Haynes BP, Smith IE, Dowsett M.

Ann Oncol. 2011 Aug;22(8):1770-6. doi: 10.1093/annonc/mdq700. Epub 2011 Feb 1.

PMID:
21285137
43.

Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.

Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, Adab F, Jefferies SJ, Scrase C, Yap BK, A'Hern RP, Sydenham MA, Emson M, Hall E; PARSPORT trial management group.

Lancet Oncol. 2011 Feb;12(2):127-36. doi: 10.1016/S1470-2045(10)70290-4. Epub 2011 Jan 12.

44.

Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers.

Miah AB, Bhide SA, Guerrero-Urbano MT, Clark C, Bidmead AM, St Rose S, Barbachano Y, A'hern R, Tanay M, Hickey J, Nicol R, Newbold KL, Harrington KJ, Nutting CM.

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):539-47. doi: 10.1016/j.ijrobp.2010.09.055. Epub 2011 Jan 13.

PMID:
21236602
45.

Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer.

Jones RL, Rojo F, A'Hern R, Villena N, Salter J, Corominas JM, Servitja S, Smith IE, Rovira A, Reis-Filho JS, Dowsett M, Albanell J.

J Clin Pathol. 2011 Feb;64(2):130-5. doi: 10.1136/jcp.2010.082966. Epub 2010 Dec 8.

PMID:
21148141
46.

Multicentric breast cancer: clonality and prognostic studies.

Eeles R, Knee G, Jhavar S, Mangion J, Ebbs S, Gui G, Thomas S, Coppen M, A'hern R, Gray S, Cooper C, Bartek J, Yarnold J.

Breast Cancer Res Treat. 2011 Oct;129(3):703-16. doi: 10.1007/s10549-010-1230-3. Epub 2010 Nov 16.

PMID:
21080063
47.

Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer.

Pinhel IF, Macneill FA, Hills MJ, Salter J, Detre S, A'hern R, Nerurkar A, Osin P, Smith IE, Dowsett M.

Breast Cancer Res. 2010;12(5):R76. doi: 10.1186/bcr2719. Epub 2010 Sep 28.

48.

Intraoperative radiotherapy for early breast cancer.

Haviland JS, A'Hern R, Bliss JM.

Lancet. 2010 Oct 2;376(9747):1142; author reply 1143-4. doi: 10.1016/S0140-6736(10)61531-0. No abstract available.

PMID:
20888982
49.

Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer.

Martin LA, Davies GL, Weigel MT, Betambeau N, Hills MJ, Salter J, Walsh G, A'Hern R, Dowsett M.

Breast Cancer Res Treat. 2010 Oct;123(3):829-36. doi: 10.1007/s10549-010-1100-z. Epub 2010 Aug 10.

PMID:
20697803
50.

Diagnostic precision of CT in local staging of colon cancers: a meta-analysis.

Dighe S, Purkayastha S, Swift I, Tekkis PP, Darzi A, A'Hern R, Brown G.

Clin Radiol. 2010 Sep;65(9):708-19. doi: 10.1016/j.crad.2010.01.024. Review.

PMID:
20696298

Supplemental Content

Loading ...
Support Center